Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that a lotion containing an alpha lipoic acid derivative increased hair diameter in chemotherapy patients with gastric or colorectal cancer, while those not using the lotion had more pronounced hair loss, suggesting potential benefits in managing chemotherapy-induced alopecia.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.